Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

Biotech Investing

Dermira (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, announced the initiation of a Phase 2b dose-ranging study evaluating the safety and efficacy of lebrikizumab in adult patients with moderate-to-severe atopic dermatitis, the most common form …

Dermira (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, announced the initiation of a Phase 2b dose-ranging study evaluating the safety and efficacy of lebrikizumab in adult patients with moderate-to-severe atopic dermatitis, the most common form of eczema.
As quoted in the press release:

“Millions of people suffer from atopic dermatitis, and despite recent treatment advances, additional therapeutic options are needed to safely and effectively manage this chronic skin condition,” said Luis Peña, chief development officer of Dermira. “Based on compelling Phase 2 proof-of-concept data in moderate-to-severe atopic dermatitis patients, we look forward to further evaluating lebrikizumab. We believe the Phase 2b dose-ranging study, with the introduction of a loading dose, as well as higher dosing regimens, will allow us to optimize the clinical profile of lebrikizumab in patients living with this debilitating condition.”

Click here to read the full press release.

The Conversation (0)
Ă—